Genitourinary Radiology: Page 20

Men may benefit from testosterone replacement
By AuntMinnieEurope.com staff writers
Male cancer survivors who develop testosterone deficiency after receiving radiation therapy and/or chemotherapy may benefit from testosterone replacement therapy, according to a U.K. study.
February 25, 2010
Biochemical failure of high-intensity ultrasound for prostate CA redefined
By Reuters Health
NEW YORK (Reuters Health), Oct 16 - An increase in prostate-specific antigen level of 1.2 ng/mL over the nadir should be considered a biochemical failure after high-intensity focused ultrasound for prostate cancer, according to authors of a paper in the October issue of BJU International.
October 15, 2009
Reuterslogo
Algeta, Bayer join forces
By AuntMinnieEurope.com staff writers
Therapeutic radiopharmaceutical developer Algeta has inked an $800 million agreement with Bayer for the development and commercialization of its Alpharadin alpha-emitting pharmaceutical for treating bone metastases.
September 7, 2009
PET/CT may help detect recurring prostate cancer earlier
By AuntMinnieEurope.com staff writers
PET/CT scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed.
September 1, 2009
Resonant to unveil new Clarity version
By AuntMinnieEurope.com staff writers
Ultrasound image-guided radiation therapy (IGRT) developer Resonant Medical will showcase the next generation of its Clarity IGRT system at next week's European Society for Therapeutic Radiology and Oncology annual meeting.
September 1, 2009
Hormone therapy ups survival of radiation-treated men with prostate cancer
By Reuters Health
NEW YORK (Reuters Health), Jul 28 - Adding hormone therapy to radiotherapy for locally advanced prostate cancer reduces disease recurrence and prolongs survival, according to a report in the August 1 issue of Cancer.
July 27, 2009
Reuterslogo
New form of radiotherapy for prostate cancer works in mice
By Reuters Health
NEW YORK (Reuters Health), Jun 18 - The alpha particle-emitting radiopeptide 213 Bi-DOTA-PESIN is effective for treating prostate cancer in mice, according to research presented at the SNM's annual meeting in Toronto this week.
June 17, 2009
Reuterslogo
SNM study: Radiopeptides for prostate cancer look promising
By AuntMinnieEurope.com staff writers
A potential new weapon in the arsenal for treating prostate cancer is being discussed at this week's SNM annual meeting in Toronto.
June 14, 2009
Brachytherapy outcomes equal bladder removal for some cancer patients
By Cynthia E. Keen
A study that compared patients in the Netherlands who received brachytherapy to those who qualified for this treatment but had a radical cystectomy instead revealed comparable survival outcomes five years after treatment.
June 9, 2009
Ferumoxtran-10 and MRI help detect metastasis of prostate cancer to lymph nodes
By Reuters Health
NEW YORK (Reuters Health), May 12 - In patients with prostate cancer, MRI with the experimental imaging agent ferumoxtran-10 (known as Combidex in the U.S.) appears to be effective in detecting lymph node metastases outside of the routine surgical area, Dutch researchers report in the May issue of Radiology.
May 11, 2009
Reuterslogo
SharpView touts image-enhancing software results
By AuntMinnieEurope.com staff writers
Swedish firm SharpView, a partner of ContextVision, has received welcome clinical results from Massachusetts General Hospital that suggest its image-enhancing software helps reduce CT radiation dose.
April 29, 2009
Varian brings RapidArc to Belgium
By AuntMinnieEurope.com staff writers
Radiation therapy firm Varian Medical Systems has installed its RapidArc radiotherapy technology at its first hospital in Belgium.
February 1, 2009
Previous Page
Page 20 of 22
Next Page